Retroperitoneal Liposarcoma Overview
Learn About Retroperitoneal Liposarcoma
Brigham And Women's Hospital, Division Of Surgical Oncology
Dr. Raut is the Chief of the Division of Surgical Oncology and the inaugural Distinguished Chair for Cancer Care at Brigham and Women's Hospital. He received a BA and BS from Stanford University, MSc from University of Oxford, and MD from Harvard Medical School, where he is also a Professor of Surgery. He completed his residency in general surgery at Massachusetts General Hospital and fellowship in surgical oncology at MD Anderson Cancer Center. Dr. Raut specializes in the multidisciplinary care of patients with soft tissue sarcoma and serves as the Surgery Director for the Center for Sarcoma and Bone Oncology at Dana-Farber Brigham Cancer Center (DFBCC). His research focuses on multimodal strategies to reduce rates of local recurrence for patients with sarcoma. Dr. Raut is rated as an Elite provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Nephrectomy, and Pancreaticoduodenectomy.
Winship Cancer Institute At Emory Midtown
Kenneth Cardona is a Surgical Oncologist in Atlanta, Georgia. Dr. Cardona has been practicing medicine for over 24 years and is rated as an Elite provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Retroperitoneal Liposarcoma, Pancreaticoduodenectomy, and Pancreatectomy.
UT MD Anderson Cancer Center
Christina Roland is a Surgical Oncologist in Cary, North Carolina. Dr. Roland is rated as an Elite provider by MediFind in the treatment of Retroperitoneal Liposarcoma. Her top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.
Summary: The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative R...
Summary: The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predi...
Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center


